BR112013026363A2 - nanossuspensões de fármaco criodessecadas - Google Patents

nanossuspensões de fármaco criodessecadas

Info

Publication number
BR112013026363A2
BR112013026363A2 BR112013026363A BR112013026363A BR112013026363A2 BR 112013026363 A2 BR112013026363 A2 BR 112013026363A2 BR 112013026363 A BR112013026363 A BR 112013026363A BR 112013026363 A BR112013026363 A BR 112013026363A BR 112013026363 A2 BR112013026363 A2 BR 112013026363A2
Authority
BR
Brazil
Prior art keywords
freeze
nanosuspensions
dried
dried drug
drug
Prior art date
Application number
BR112013026363A
Other languages
English (en)
Other versions
BR112013026363B1 (pt
Inventor
Henning Gieseler
Jakob Andreas Beirowski
Sabine Karine Katrien Inghelbrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112013026363A2 publication Critical patent/BR112013026363A2/pt
Publication of BR112013026363B1 publication Critical patent/BR112013026363B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "nanossuspensões de fármaco criodessecadas". a presente invenção refere-se a uma nanossuspensão de fármaco criodessecada (também chamada liofilizada). a presente composição de nanossuspensão de fármaco criodessecada tem uma estabilidade aceitável da distribuição do tamanho das partículas durante o armazenamento, incluindo armazenamento a longo prazo.
BR112013026363-6A 2011-04-15 2012-04-13 Nanossuspensões compreendendo 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil] amino] benzonitrila, seu processo de preparação e composição farmacêutica para administração por injeção intramuscular ou subcutânea BR112013026363B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475811P 2011-04-15 2011-04-15
US61/475,811 2011-04-15
PCT/EP2012/056818 WO2012140220A1 (en) 2011-04-15 2012-04-13 Freeze dried drug nanosuspensions

Publications (2)

Publication Number Publication Date
BR112013026363A2 true BR112013026363A2 (pt) 2016-12-27
BR112013026363B1 BR112013026363B1 (pt) 2021-10-13

Family

ID=45937395

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026363-6A BR112013026363B1 (pt) 2011-04-15 2012-04-13 Nanossuspensões compreendendo 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil] amino] benzonitrila, seu processo de preparação e composição farmacêutica para administração por injeção intramuscular ou subcutânea

Country Status (21)

Country Link
US (5) US20140038996A1 (pt)
EP (2) EP2696848B1 (pt)
JP (1) JP6161593B2 (pt)
CN (2) CN103764117A (pt)
AU (1) AU2012241726C1 (pt)
BR (1) BR112013026363B1 (pt)
CA (1) CA2832410C (pt)
CY (1) CY1123434T1 (pt)
DK (1) DK2696848T3 (pt)
ES (1) ES2823805T3 (pt)
HK (1) HK1257447A1 (pt)
HR (1) HRP20201241T1 (pt)
HU (1) HUE050970T2 (pt)
LT (1) LT2696848T (pt)
MX (1) MX362344B (pt)
PL (1) PL2696848T3 (pt)
PT (1) PT2696848T (pt)
RS (1) RS60651B1 (pt)
RU (1) RU2643062C2 (pt)
SI (1) SI2696848T1 (pt)
WO (1) WO2012140220A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3656393T (pt) * 2011-04-28 2022-11-03 Oncopeptides Ab Preparação liofilizada de dipéptidos citotóxicos
CA2889753C (en) 2012-10-26 2021-03-02 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
KR102121404B1 (ko) * 2013-03-15 2020-06-11 썬 파마 글로벌 에프제트이 아비라테론 아세테이트 제제
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
HUP1500055A1 (hu) * 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
CN105902496B (zh) * 2016-04-18 2019-10-25 沈阳药科大学 一种纳米混悬液固体化过程的处理方法
US10507165B2 (en) * 2017-05-31 2019-12-17 Adienne Pharma & Biotech Sa Multi chamber flexible bag and methods of using same
RU2665383C9 (ru) * 2017-06-22 2019-07-23 Общество с ограниченной ответственностью "Вириом" Фармацевтическая наносуспензия для терапии ВИЧ-инфекции
WO2019012100A1 (en) 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS
RU2721562C1 (ru) * 2019-06-04 2020-05-20 Автономная некоммерческая образовательная организация высшего образования "Сколковский институт науки и технологий" Способ загрузки неорганических наночастиц или органических молекул в пористые частицы микронного или субмикронного размера
CN111149795A (zh) * 2020-01-14 2020-05-15 成都艾伟孚生物科技有限公司 一种冷冻保护剂及其应用和一种精子冷冻液及其制备方法
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
US20230201369A1 (en) * 2020-04-29 2023-06-29 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
KR20230038521A (ko) 2020-07-09 2023-03-20 얀센 파마슈티카 엔.브이. 장기 작용 제형
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
JP6886551B1 (ja) * 2020-11-06 2021-06-16 医療法人祥和会 歯科用の局所麻酔液
CN112641950B (zh) * 2021-01-12 2022-12-16 北京德立福瑞医药科技有限公司 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法
WO2023108156A1 (en) * 2021-12-11 2023-06-15 Beloteca, Inc. Ziprasidone formulations
WO2023154454A1 (en) * 2022-02-10 2023-08-17 Soligenix, Inc. Telmisartan nanosuspension for therapy of respiratory infections and methods of making and using same
WO2023203257A1 (en) * 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company Freeze dried compositions
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
CN116115621A (zh) * 2022-10-31 2023-05-16 广州鹏兴医药科技有限公司 氢氯噻嗪组合物及其制备方法及氢氯噻嗪微针透皮贴剂
CN116919898B (zh) * 2023-09-15 2023-12-19 北京星辉再生科技有限责任公司 米诺地尔纳晶混悬液组合物、米诺地尔纳晶混悬液及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006511525A (ja) 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
RU2331424C2 (ru) * 2002-12-13 2008-08-20 Джеготек Аг Топический состав, содержащий наночастицы спиронолактона
CN101166514A (zh) * 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
EP1954252B1 (en) 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
BRPI0713334B1 (pt) * 2006-06-23 2024-02-20 Janssen Sciences Ireland Uc Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
AU2008274185B2 (en) * 2007-07-12 2014-07-03 Janssen Sciences Ireland Uc Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
US8161810B2 (en) 2008-01-29 2012-04-24 Carefusion 303, Inc. Syringe imaging systems
CN101283982B (zh) * 2008-06-03 2010-06-02 南京工业大学 非诺贝特纳米混悬剂及其制备方法
CN101904820A (zh) * 2009-06-02 2010-12-08 姜玲敏 槲皮素纳米混悬剂冻干组合物及其制备方法和应用
CN101612131B (zh) * 2009-07-17 2011-09-14 郑州大学 2-甲氧基雌二醇纳米混悬剂冻干粉及其制备方法
CN101953808B (zh) * 2010-10-13 2013-03-13 厦门大学 抗肿瘤化合物去乙酰真菌环氧乙酯注射剂及其制备方法

Also Published As

Publication number Publication date
HK1257447A1 (zh) 2019-10-18
CN108210469A (zh) 2018-06-29
US20220409616A1 (en) 2022-12-29
LT2696848T (lt) 2020-09-10
RU2013150803A (ru) 2015-05-20
CA2832410C (en) 2019-07-23
CN103764117A (zh) 2014-04-30
US11389448B2 (en) 2022-07-19
US20160317534A1 (en) 2016-11-03
SI2696848T1 (sl) 2020-10-30
US11819502B2 (en) 2023-11-21
CY1123434T1 (el) 2021-12-31
RU2643062C2 (ru) 2018-01-30
EP2696848B1 (en) 2020-07-22
DK2696848T3 (da) 2020-10-12
US20190076428A1 (en) 2019-03-14
MX2013011985A (es) 2013-11-04
HRP20201241T1 (hr) 2020-11-27
EP2696848A1 (en) 2014-02-19
US20140038996A1 (en) 2014-02-06
AU2012241726B2 (en) 2017-04-27
RS60651B1 (sr) 2020-09-30
US10166231B2 (en) 2019-01-01
MX362344B (es) 2019-01-11
PL2696848T3 (pl) 2020-12-28
CA2832410A1 (en) 2012-10-18
JP6161593B2 (ja) 2017-07-12
WO2012140220A1 (en) 2012-10-18
HUE050970T2 (hu) 2021-01-28
EP3799860A1 (en) 2021-04-07
AU2012241726C1 (en) 2017-09-14
ES2823805T3 (es) 2021-05-10
BR112013026363B1 (pt) 2021-10-13
JP2014515021A (ja) 2014-06-26
PT2696848T (pt) 2020-09-03
US20240148726A1 (en) 2024-05-09
AU2012241726A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
BR112013026363A2 (pt) nanossuspensões de fármaco criodessecadas
JOP20180102B1 (ar) مركب صيدلاني
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
NZ702663A (en) Nuclear transport modulators and uses thereof
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
BR112015012547A2 (pt) composições de prostaciclina e métodos de sua utilização
MX348823B (es) Formulaciones estables de linaclotida.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112012019190A2 (pt) composições de cuidado oral.
MX2013004061A (es) Analogos de ciclosporina.
BR112012019997A2 (pt) composições de cuidado oral
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
IN2014DN09347A (pt)
MX2013004062A (es) Analogos de ciclosporina.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.
NZ717192A (en) Anti-inflammatory tripeptides
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/04/2012, OBSERVADAS AS CONDICOES LEGAIS.